GDF-11

GDF-11 (growth differentiation factor 11) is a member of the TGF-β superfamily and a close homologue of myostatin (GDF-8) — the two share signaling machinery (ActRIIB → SMAD2/3), though GDF-11 is expressed at far lower levels. It gained attention in aging research after reports that its circulating level declines with age and that giving it to old mice reversed some age-related changes. That "rejuvenation factor" narrative is genuinely contested in the scientific literature. GDF-11 is not approved and is supplied for research use only.

What is GDF-11 and why is it studied in aging?

GDF-11 came to prominence from heterochronic parabiosis experiments — sharing young and old mouse circulation — where a 2013 study reported that GDF-11 is a circulating factor that declines with age and that restoring it reversed age-related cardiac hypertrophy in old mice; related reports described improvements in brain and skeletal-muscle measures. It has documented roles in embryonic patterning, erythropoiesis, and cardiac biology, and appears to act partly on brain vasculature rather than crossing the blood-brain barrier.

Source: Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy, Loffredo F.S., Steinhauser M.L., Jay S.M., Gannon J., Pancoast J.R., Yalamanchi P., Sinha M., … Wagers A.J., Lee R.T., Cell, 2013

Is GDF-11 actually a proven anti-aging compound?

No — this is the crux, and honesty matters here: the original finding that GDF-11 declines with age was directly challenged: a 2015 study reported the opposite — that GDF-11 increases with age and inhibits skeletal-muscle regeneration — and argued the earlier results were confounded because common assays and antibodies cannot cleanly distinguish GDF-11 from myostatin (GDF-8), whose mature signaling domains are about 89% identical, and several groups have reported conflicting results on its effects. Additional problems include lot-to-lot variability in commercial recombinant GDF-11 and the argument that circulating GDF-11 may be unable to outcompete myostatin for ActRIIB. The rejuvenation claims should be read as an open, disputed research question — not established fact.

Sources: GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration, Egerman M.A., et al. (optional, non-blocking: complete list), Cell Metabolism, 2015; Similar sequences but dissimilar biological functions of GDF11 and myostatin, Suh J., Lee Y.-S., Experimental & Molecular Medicine, 2020 · Evidence level: preclinical and contested

What are the safety concerns and regulatory status?

GDF-11 is not approved, has no established human safety profile, and its TGF-β-family activity (including proangiogenic effects linked in some studies to cancer biology) warrants caution. No interventional human clinical trial of administered GDF-11 has been published as of August 2026; the entire evidence base is preclinical (mouse parabiosis and injection studies) and observational (circulating-level measurements, which are themselves complicated by the myostatin cross-reactivity above). Claims of "rejuvenation" in humans are not supported by clinical data. See the legal status guide.

How does GDF-11 relate to myostatin inhibitors?

GDF-11 is the ligand; compounds like Follistatin and the discontinued ACE-031 actually trap or neutralize GDF-11 (among other ligands) — so GDF-11 and those inhibitors sit on opposite sides of the same ActRIIB pathway. GDF-11 (growth differentiation factor 11, also GDF-8's closest relative) and myostatin (GDF-8) are both TGF-β-superfamily ligands that signal through ActRIIB; their mature domains are ~89% identical, which is why they are pharmacologically similar and why recombinant preparations and immunoassays are notoriously hard to tell apart — a fact at the center of the GDF-11 aging controversy. That relationship is worth understanding when comparing muscle- and longevity-oriented compounds.

Source: Similar sequences but dissimilar biological functions of GDF11 and myostatin, Suh J., Lee Y.-S., Experimental & Molecular Medicine, 2020

Why does vendor verification matter, and how does Peptigrity verify?

Because commercial recombinant GDF-11 is known for lot-to-lot variability and is easily confused analytically with myostatin, HPLC purity and mass-spec identity confirmation are essential. Peptigrity collects independent third-party Certificates of Analysis for GDF-11 from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate; the trust score weights independent lab purity and community reviews equally (50/50). (No GDF-11 lab tests are on file yet — 0 tests is expected for a compound with essentially no legitimate research-supply market.) See how to read lab results.

Educational information only; not medical advice. GDF-11's anti-aging role is scientifically contested and it is not approved for human use. Consult a qualified healthcare provider. Peptigrity does not sell, endorse, or recommend products or vendors.

Frequently asked questions